Abstract: Introduction: The rapidly growing field of regenerative medicine incorporates fundamental principles of stem cell biology and biomedical engineering to repair tissues damaged by genetic disorder, degeneration, or traumatic injury. The global market for stem cell therapies is expanding at an accelerating rate and projected to triple to over 100 Billion USD by the end of the decade (No author listed, 2019), as per Figure 1A. However, the full market and health potential of regenerative therapies depends upon successful clinical translation of contemporary treatments, such as cell replacement therapy. Replacement strategies offer newfound promise to treat vision loss caused by degeneration of the retina, a photosensitive tissue that lines the back of the human eye to convert light into bioelectrical signals for vision. Retinal disorders, such as macular degeneration and diabetic retinopathy, are leading causes of irreversible blindness in adults and are projected to increase in prevalence in the coming decades (GBD 2019 Blindness and Vision Impairment Collaborators, 2021). Emerging cell replacement strategies (No author listed, 2019; GBD 2019 Blindness and Vision Impairment Collaborators and Vision Loss Expert Group of the Global Burden of Disease Study, 2021) showcase innovative treatments for vision loss that will dramatically increase the current market share for retinal therapeutics.